Millennium spent $1.3M on lobbying

According to public records, Millennium Pharmaceuticals spent $1.3 million in 2007 lobbying the federal government on patent reform and biotech drug regulation. A bill--currently in the Senate--had drawn the ire of pharmaceutical companies. Among other things, the bill calls a reduction in the number of patent infringement lawsuits and the institution of a post-approval patent re-evaluation process. Pharma companies fear that such a law would weaken patent protection. Amgen also spent a chunk of money lobbying against the patent bill.

Millennium also lobbied for legislation that would pave the way for approval of generic biotech drugs. You can bet Amgen wasn't with them on that one.

- see this Forbes article
- read the AP report on Amgen's activities

ALSO: Pharma may be giving big bucks to presidential candidates--$9.1 million so far--but it's surpassed by 16 other industries, according to the Center for Responsive Politics. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.